Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
52 participants
INTERVENTIONAL
2015-11-30
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study is expected to last approximately 12 weeks (with screening evaluations up to 4 weeks prior).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY3305677 in Healthy Participants
NCT02972645
A Study of LY3361237 in Healthy Participants
NCT03695198
A Study of LY3025876 in Healthy Volunteers
NCT01528124
A Study of LY3045697 in Healthy Participants
NCT01750853
A Study of LY3053102 in Healthy Participants
NCT01736241
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo (SC)
Single subcutaneous (SC) dose of placebo
Placebo (SC)
Administered SC
LY3200327 (SC)
Single escalating subcutaneous (SC) dose of LY3200327
LY3200327 (SC)
Administered SC
LY3200327 (IV)
Single intravenous (IV) dose of LY3200327
LY3200327 (IV)
Administered IV
Placebo (IV)
Single intravenous (IV) dose of placebo
Placebo (IV)
Administered IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo (SC)
Administered SC
LY3200327 (SC)
Administered SC
LY3200327 (IV)
Administered IV
Placebo (IV)
Administered IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* First-generation healthy Japanese (age 20 to 65 years) will be included
Exclusion Criteria
* Chronic infection
* Treatment with prohibited medications
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parexel International/ California Clinical Trials
Glendale, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I8C-MC-GSFA
Identifier Type: OTHER
Identifier Source: secondary_id
15577
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.